Cardiac Calcium Channel Blocker Therapy is a medical approach that plays a pivotal role in managing cardiovascular conditions. These blockers, also known as calcium antagonists, work by inhibiting the influx of calcium ions into the cardiac muscle cells, thereby reducing the workload on the heart. This therapeutic intervention is particularly beneficial in conditions such as hypertension, angina, and certain arrhythmias. By dilating blood vessels and relaxing the heart, calcium channel blockers help improve blood flow and reduce the strain on the cardiovascular system. Clinicians often prescribe these medications as part of a comprehensive treatment plan for individuals with various cardiovascular disorders. As with any medical therapy, it is essential for healthcare providers to tailor the prescription based on the patient's specific health profile and needs, ensuring optimal efficacy while minimizing potential side effects. The evolving landscape of Cardiac Calcium Channel Blocker Therapy continues to contribute significantly to advancements in cardiovascular medicine, enhancing the quality of care for patients with heart-related conditions.
Title : A diabetic sweetheart facing a sour ending!
Ahdy Wadie Helmy, Indiana University School of Medicine, United States
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Cardiovascular nanomedicine: Stopping strokes, unclogging arteries and restoring heart function
Thomas J Webster, Hebei University of Technology, China
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Perception of cardiovascular risk in women after a rehabilitation program
Maria Teresa Carvallo Marin, Privado, Chile